aptinyx inc logo

Aptinyx Inc

Aptinyx, Inc. is a biopharma company, focusn on discovery and development of innovative therapies and drug candidate for challenging disorders of the brain and nervous system.

Aptinyx is preclinical pipeline spun out of Naurex, which was acquired by Allergan in Aug 2015. The top management team of Naurex retains and formed the major part of Aptinyx team.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”APTX” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.aptinyx.com
Founded2015
Disease Focus
Development Stage
STOCK CODENASDAQ: APTX
Address
909 Davis Street, Suite 600, IL 60201
Evanston
United States
Email
Contact Number
847-871-0377

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/aptinyx-inc-” connections=”true” suffix=””]

Aptinyxs therapeutics modulate NMDA receptors and are designed to enhance synaptic plasticity. Its platform was developed based on research of Joseph Moskal, Prof. biomedical engineering at Northwestern University, director of the universitys Falk Center for Molecular Therapeutics, founder of Naurex, and chief scientific officer of Aptinyx.

In May 2018 Allergan exercised an option under ongoing research collaboration to acquire AGN-241751. Aptinyxs therapeutics will receive no further economic consideration from this product candidate.

Dec 2017, Aptinyx Raises $70 Million in Series B Financing led by Bain Capital Life Sciences. Additional new investors include Adage Capital, Agent Capital, HBM Healthcare Investments, Nan Fung Life Sciences, Partner Fund Management, and Rock Springs Capital. Existing investors also participated New Leaf Venture Partners, Frazier Healthcare Partners, Longitude Capital, Osage University Partners, Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty OKeefe & Company, and Northwestern University.

In May 2016, completed a $65 Mn Series A financing round led by New Leaf Venture Partners. Other investors include Frazier Healthcare Partners, Longitude Capital, Osage University, Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty OKeefe & Company and Northwestern University.